ArticleDiabetes2010
Unacylated ghrelin rescues endothelial progenitor cell function in individuals with type 2 diabetes.
Article in Diabetes, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 76 citations in OpenAlex.
- Beyond Hunger: The Structure, Signaling, and Systemic Roles of Ghrelin.International journal of molecular sciences · 2025Review
- Heal the heart through gut (hormone) ghrelin: a potential player to combat heart failure.Heart failure reviews · 2021Review
- The Good, the Bad and the Unknown Aspects of Ghrelin in Stress Coping and Stress-Related Psychiatric Disorders.Frontiers in synaptic neuroscience · 2020Review
- Unacylated Ghrelin Improves Vascular Dysfunction and Attenuates Atherosclerosis during High-Fat Diet Consumption in Rodents.International journal of molecular sciences · 2019Article
- The Future Challenge of Reactive Oxygen Species (ROS) in Hypertension: From Bench to Bed Side.International journal of molecular sciences · 2017Review
- Unacylated ghrelin prevents mitochondrial dysfunction in a model of ischemia/reperfusion liver injury.Cell death discovery · 2017Article
- Ghrelin, MicroRNAs, and Critical Limb Ischemia: Hungering for a Novel Treatment Option.Frontiers in endocrinology · 2017Review
- The Impact of Ghrelin in Metabolic Diseases: An Immune Perspective.Journal of diabetes research · 2017Review
- Unacylated ghrelin modulates circulating angiogenic cell number in insulin-resistant states.Diabetology & metabolic syndrome · 2017Article
- Article
- Article
- Insights into the molecular mechanisms of diabetes-induced endothelial dysfunction: focus on oxidative stress and endothelial progenitor cells.Endocrine · 2015Article
- Unacylated ghrelin restores insulin and autophagic signaling in skeletal muscle of diabetic mice.Pflugers Archiv : European journal of physiology · 2015Article
- Inverse association of des-acyl ghrelin with worksite blood pressure in overweight/obese male workers.Environmental health and preventive medicine · 2015Article
- Antifibrotic activity of acylated and unacylated ghrelin.International journal of endocrinology · 2015Review
- Ghrelin: ghrelin as a regulatory Peptide in growth hormone secretion.Journal of clinical and diagnostic research : JCDR · 2014Review
- Unacylated ghrelin suppresses ghrelin-induced neuronal activity in the hypothalamus and brainstem of male rats [corrected].PloS one · 2014Article
- Unacylated ghrelin promotes skeletal muscle regeneration following hindlimb ischemia via SOD-2-mediated miR-221/222 expression.Journal of the American Heart Association · 2013Article
- Review
- Clinical review: The human experience with ghrelin administration.The Journal of clinical endocrinology and metabolism · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAcylated ghrelin (AG) is a diabetogenic and orexigenic gastric polypeptide. These properties are not shared by the most abundant circulating form, which is unacylated (UAG). An altered UAG/AG profile together with an impairment of circulating endothelial progenitor cell (EPC) bioavailability were found in diabetes. Based on previous evidence for the beneficial cardiovascular effects of AG and UAG, we investigated their potential to revert diabetes-associated defects. RESEARCH DESIGN AND
methodsHealthy human subjects, individuals with type 2 diabetes, and ob/ob mice were AG or UAG infused. EPC mobilization in patients and mice was evaluated, and the underlying molecular mechanisms were investigated in bone marrow stromal cells. Recovered EPCs were also evaluated for the activity of senescence regulatory pathways and for NADPH oxidase activation by knocking down p47(phox) and Rac1. Finally, UAG modulation of human EPC vasculogenic potential was investigated in an in vivo mouse model.
resultsNeither AG nor UAG had any effect in healthy subjects. However, systemic administration of UAG, but not AG, prevented diabetes-induced EPC damage by modulating the NADPH oxidase regulatory protein Rac1 and improved the vasculogenic potential both in individuals with type 2 diabetes and in ob/ob mice. In addition, unlike AG, UAG facilitated the recovery of bone marrow EPC mobilization. Crucial to EPC mobilization by UAG was the rescue of endothelial NO synthase (eNOS) phosphorylation by Akt, as UAG treatment was ineffective in eNOS knockout mice. Consistently, EPCs expressed specific UAG-binding sites, not recognized by AG.
conclusionsThese data provide the rationale for clinical applications of UAG in pathologic settings where AG fails.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.